ホーム › 慢性リンパ性白血病 › ミシガン州

ミシガン州における慢性リンパ性白血病の臨床試験

ミシガン州内の拠点で、慢性リンパ性白血病に関する12件の研究が参加者を募集しています。

ミシガン州内の都市

公式研究テキスト（英語）

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
他4件

被験者募集中第3相

65歳以上 · 全性別 · 2026/10/02更新 · NCT07321652

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

MyMichigan Medical Center Gratiot, Alma
MyMichigan Medical Center Alpena, Alpena
Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
他68件

被験者募集中観察研究健康なボランティア歓迎

40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Bronson Battle Creek, Battle Creek
Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
他43件

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/30更新 · NCT04269902

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

The Cancer and Hematology Centers, Grand Rapids

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/28更新 · NCT06943872

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Karmanos Cancer Institute, Detroit

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/09/28更新 · NCT05006716

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Corewell Health the Michigan Cancer Consortium, Grand Rapids

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/28更新 · NCT06846671

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Karmanos Cancer Institute, Detroit

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/28更新 · NCT06973187

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011), Grand Rapids

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/24更新 · NCT06136559

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Karmanos Cancer Center, Detroit

被験者募集中第2相

18歳以上 · 全性別 · 2026/09/17更新 · NCT07221500

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

West Michigan Cancer Center, Kalamazoo

被験者募集中観察研究

18歳以上 · 全性別 · 2026/05/07更新 · NCT02269592

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Henry Ford Hospital /ID# 270973, Detroit

被験者募集中第3相

18歳以上 · 全性別 · 2026/04/09更新 · NCT06428019

HPC Offered for PRESERVE Expansion

Henry Ford Health, Detroit

被験者募集中観察研究

12歳〜80歳 · 全性別 · 2025/08/28更新 · NCT07145411

ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。